Financials and Estimates

Financials and Estimates

Marzetti's operating income rose 56% between fiscal 2023 and fiscal 2025, but 62% of the increase came from gross-margin expansion and 25% from restructuring charges falling away, not from selling more. The first nine months of fiscal 2026 broke that pattern: reported earnings per share rose 6.5%, while on the company's own per-share adjustments they were flat at $5.37 and operating income fell 0.2%. Consensus for fiscal 2027 assumes both re-accelerate.

The three-year record

Source: FY2025 Annual Report (Form 10-K), Results of Consolidated Operations [1] and Consolidated Statements of Cash Flows [2].

Across the three fiscal years the company reports in full, net sales grew from $1,822.5 million to $1,909.1 million — a compound rate of 2.4% a year — while diluted earnings per share went from $4.04 to $6.07, a compound rate of 22.6% [3]. The gap between those two rates is where the period's earnings growth came from, and it sits in two places: gross margin and restructuring charges.

Source: FY2025 Annual Report (Form 10-K), Results of Consolidated Operations [4].

Operating income rose $78.8 million over the two years. Splitting that increase into its parts: sales growth of $86.6 million, earned at the fiscal 2023 gross margin of 21.3%, is worth $18.5 million; the 260-basis-point rise in gross margin to 23.9% applied to fiscal 2025 sales is worth $48.6 million; overheads absorbed $8.1 million; and restructuring and impairment charges, which ran at $25.0 million in fiscal 2023 as the company exited its perimeter-of-the-store bakery lines, fell to $5.1 million, releasing $19.9 million [5] [6].

Source: derived from the FY2025 Annual Report (Form 10-K) three-year results table; components computed at reported margins [7].

Two-thirds of the earnings recovery, then, is a cost result, and a further quarter is the absence of charges the company was taking in the base year. Management's own adjusted measure makes the same point more gently: adjusted operating income, which strips restructuring and acquisition costs from both years, rose 5.7% in fiscal 2025 to $229.2 million against reported growth of 10.5% [8]. Fiscal 2025 also carried a $14.0 million pension settlement charge below the operating line, from terminating five frozen defined-benefit plans, which cut reported earnings per share by roughly $0.39 [9]. That charge matters more than its size suggests, because it is the reference point for how fiscal 2026 looks.

Balance sheet and cash

Sources: FY2025 Annual Report (Form 10-K) balance sheet [10] and cash flow statement [11]; FY2023 equity from the FY2024 Annual Report balance sheet [12]; FY2022 equity from the FY2023 Annual Report balance sheet [13]; returns derived from those figures.

The returns are the reason the business earns a premium multiple in the first place. With no debt on the balance sheet in any of the three years [14], return on average equity ran at 17.4% in fiscal 2025 and return on invested capital net of cash at 20.6%, against 13.0% and 14.2% in fiscal 2023 — the same margin recovery showing up in the return measure. Operating cash flow was 2.03 times net income in fiscal 2023 and 1.56 times in fiscal 2025 [15], which is what happens when a working-capital release in the base year is not repeated rather than a sign of deteriorating quality.

Capital intensity fell sharply over the period — capex of $90.2 million in fiscal 2023 against $58.0 million in fiscal 2025 [16] — and management has guided fiscal 2026 back up to approximately $80 million [17]. Free cash flow of $203.5 million in fiscal 2025 covered the $103.5 million dividend twice over, before the balance sheet changed shape (Business and De-Rating).

The first nine months of fiscal 2026

Nine-month net sales rose 2.2% to $1,464.8 million. The company's own decomposition of that increase is where the reading starts to diverge from the headline: core sales volume and mix subtracted $2.4 million, net pricing added $15.1 million, and a temporary supply agreement — a transitional arrangement to keep supplying the seller of the Atlanta plant Marzetti bought in February 2025 — added $18.4 million [18].

Source: Q3 FY2026 Form 10-Q, Breakdown of % Change in Consolidated Net Sales [19].

The temporary supply agreement is disclosed separately in the revenue note at $20.4 million of nine-month Foodservice sales against $2.1 million a year earlier, and it is already winding down — third-quarter supply-agreement sales were $1.5 million against $2.1 million [20]. Excluding it, adjusted net sales rose 0.9% and adjusted pounds shipped fell 0.6% [21].

Below the sales line, the pattern of the prior three years reversed. Gross profit rose $13.7 million and gross margin gained 40 basis points, the eleventh consecutive quarter of year-on-year gross-margin improvement on management's count [22]. Selling, general and administrative expense rose $12.1 million, or 7.2%, on higher marketing, compensation and IT spending plus $3.5 million of Bachan's acquisition costs, and a $2.0 million net restructuring and impairment charge appeared where there had been none [23]. Operating income fell $0.4 million to $181.0 million [24].

Source: Q3 FY2026 Form 10-Q, Condensed Consolidated Statements of Income [25] and Results of Consolidated Operations [26].

Reported diluted earnings per share for the nine months were $5.21 against $4.89, up 6.5% [27]. The 10-Q itemises what sat inside each figure: in fiscal 2026, Bachan's acquisition costs cut $0.10 and the net restructuring charge $0.06; in fiscal 2025, the pension settlement cut $0.39 and Atlanta plant acquisition costs $0.09 [28]. Adding each period's own disclosed items back puts both nine-month figures at $5.37. On the company's own adjustments, per-share earnings were unchanged year on year, and the entire reported increase is the prior year's charges not repeating.

The strongest fact against reading that as deterioration is that like-for-like operating income still grew: adjusted operating income rose $1.8 million to $186.6 million, or about 1% [29]. Roughly $0.08 of the flat adjusted per-share result is non-operating: the effective tax rate rose to 22.7% from 22.0%, and other non-operating income fell $1.1 million as the pre-acquisition cash pile was spent down [30] [31]. Gross margin is still expanding while overhead growth absorbs the gain, an absorption sized and bounded in Margin Runway.

Inside the business the movement was not uniform. Nine-month Retail segment operating income fell 6.0% to $160.5 million as segment margin slipped to 21.1% from 22.4%, while Foodservice rose 19.6% to $98.9 million; unallocated corporate expense rose 6.8% to $77.0 million [32]. The licensed Retail portfolio and the shipment-versus-consumption gap behind the Retail decline are traced in The Licensing Engine.

Where the cash came from

Nine-month operating cash flow rose 31.9% to $228.7 million, a figure management highlighted on the call [33]. The $55.3 million increase decomposes cleanly, and only a minority of it is earnings.

Source: derived from the Q3 FY2026 Form 10-Q, Condensed Consolidated Statements of Cash Flows [34].

The single largest item is a $24.7 million swing in deferred income taxes, which the 10-Q attributes to timing benefits from the One Big Beautiful Bill Act enacted in July 2025 — legislation that accelerated deductions for domestic research spending and bonus depreciation, with no material effect on the effective tax rate [35] [36]. Cash income tax payments fell to $24.8 million from $42.2 million [37]. That is real cash, but it is a shift in timing that unwinds as the accelerated deductions are used up, not a change in earning power. The second largest, a $27.1 million working-capital swing, is largely the absence of the prior year's receivable and inventory build. Underlying cash generation improved; it improved by considerably less than 32%.

What the forward estimates carry

Fiscal 2026 ended on 30 June 2026 and has not yet been reported — no fourth-quarter release or Form 10-K had been filed as of late July 2026 — so both the current and the following year are consensus figures rather than results.

Source: consensus estimates as at 29 July 2026, from the report's market-data feed; no filing page backs these figures.

Source: consensus estimate revision history as at 29 July 2026, from the report's market-data feed; no filing page backs these figures.

Three things are worth extracting from that table. First, the direction: the fiscal 2026 estimate has come down 3.8% in ninety days and fiscal 2027 by 1.8%, with four downward revisions recorded on each in the trailing thirty days. The ninety-day mark sits just before the 4 May third-quarter release, which reported $1.35 against a consensus that then stood at $1.57 — a 14% shortfall. The cuts followed the print rather than anticipating it.

Second, the panel is thin and internally inconsistent. Between three and six analysts contribute to any single line. The fiscal-year earnings panel implies a June-quarter result of $1.53 ($6.745 less the $5.21 already reported), while the June-quarter panel itself says $1.40 — and on revenue the fiscal-year panel implies a June quarter of $460.6 million against the quarterly panel's $476.0 million. The $15.4 million revenue gap is close to the scale of a partial-quarter Bachan's contribution, which suggests the annual revenue line has not been fully updated for a deal that closed on 1 May 2026 [38]. Either way, these are not deeply sampled numbers, and small-panel consensus should be treated as a rough marker rather than a forecast.

Third, and most consequential: both years assume a re-acceleration that the reported nine months do not yet show. Taking the more current construction — nine months actual plus the June-quarter panel — fiscal 2026 lands at about $1,940.8 million of sales and $6.61 of earnings per share. Fiscal 2027 consensus of $2,018.9 million is $78 million above that. Bachan's should supply roughly $75 million of incremental revenue in its first full year, on management's guidance to a run rate moderately above the $87 million the brand reported in calendar 2025, against a two-month stub in fiscal 2026 [39]. The temporary supply agreement, worth about $21 million in fiscal 2026, disappears. Netting those leaves roughly $20 million to $25 million, a little over 1% of the base, to come from the underlying business — against nine-month core volume and mix of minus 0.2% and adjusted pounds shipped of minus 0.6%.

The earnings step is the harder one. Fiscal 2027 consensus of $7.22 is 9.2% above the $6.61 construction, about $16.6 million of additional net income. Bachan's contributes at "an operating margin similar to The Marzetti Company's current level" on management's guidance [40] — roughly $8 million to $9 million of incremental operating income on the $75 million of net new revenue left after the two-month fiscal 2026 stub, before any amortisation of acquired intangibles, which cannot yet be estimated because the purchase price allocation will not be filed until the fiscal 2026 Form 10-K. Against it sits the financing: interest on the $200 million term loan at a rate management described as currently below 5% [41]. Underwriting Bachan's owns that arithmetic and sets the first full year at about $18 million of pre-tax cost against $10 million to $12 million of acquired operating income on the brand's full $87 million to $95 million sales base; the lower contribution figure used here is the same guided margin applied to the smaller incremental base.

On that arithmetic, the acquisition is close to earnings-neutral in its first full year, and essentially all of the 9.2% consensus growth has to come from the base business — the same base business whose nine-month operating income fell 0.2% and whose adjusted per-share earnings were flat. The credible route to it exists: the Milpitas plant closure completed in August 2025 [42] and the network optimisation behind it carry savings into fiscal 2027, the fiscal 2025 fourth quarter absorbed the full $5.1 million of that year's restructuring charges [43] and will not repeat, and Bachan's is margin-accretive at the gross line even if it is not at the operating line while the brand is being built [44]. The route requires the productivity program to outrun overhead growth, which it has not done for three quarters.

At $110.19 on 28 July 2026, the shares trade at 16.3 times the fiscal 2026 consensus and 15.3 times fiscal 2027, with a $4.00 annualised dividend representing 59% of the fiscal 2026 estimate. The estimates are the more fragile half of those ratios.

What would change the read

The June quarter is structurally the weakest of Marzetti's year: fiscal 2025's fourth quarter produced $38.9 million of operating income on $475.4 million of net sales, an 8.2% margin against 11.5% for the full year [45]. Reaching even the lower $1.40 of the two consensus constructions, against $1.18 reported in the June 2025 quarter, requires roughly $51 million of operating income against that $38.9 million reported and about $44.4 million adjusted [46] [47] [48]. About $5.1 million of that gap is the restructuring charge not repeating and a few million more the Bachan's stub; the rest has to be operational. A June quarter that clears $1.40 with overhead growth back below gross-profit growth would argue the nine-month pattern was an investment year rather than a plateau. A June quarter near $1.20, with selling and administrative expense still compounding at 7% or more, would put the fiscal 2027 consensus roughly a full year ahead of the business.

The other item to watch is disclosure rather than performance: the fiscal 2026 Form 10-K will carry the Bachan's purchase price allocation, and with it the amortisation charge that the consensus models currently cannot see. A large allocation to definite-lived intangibles would take a further bite out of reported earnings without touching cash.

Web research was unavailable for this run, so no broker-level detail behind the consensus figures, and no post-quarter commentary, could be verified beyond the market-data feed described above.